Research programme: cyclo-oxygenase inhibitors - SulfidrisAlternative Names: ACS 18; ACS 27
Latest Information Update: 16 Jul 2016
At a glance
- Originator Sulfidris
- Mechanism of Action Cyclooxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Colorectal-cancer(Prevention) in Italy
- 17 Aug 2007 Preclinical trials in Colorectal cancer prevention in Italy (unspecified route)